Accumulating data show that the phenotypes and functions of distinctive mucosal dendritic cells (DCs) in the gut are regulated by retinoic acid (RA). Unfortunately, the exact role of butyrate in RA-mediated mucosal DC differentiation has not been elucidated thoroughly to date. Mucosal-like dendritic cell differentiation was completed in vitro by culturing bone marrow cells with growth factors [granulocyte-macrophage colonystimulating factor (GM-CSF/interleukin (IL)-4], RA and/or butyrate. The phenotypes, cytokine secretion, immune functions and levels of retinal dehydrogenase of different DCs were detected using quantitative polymerase chain reaction (qPCR), enzyme-linked immunosorbent assay (ELISA) and flow cytometry, respectively. The results showed that RA-induced DCs (RADCs) showed mucosal DC properties, including expression of CD103 and gut homing receptor a 4 b 7 , low proinflammatory cytokine secretion and low priming capability to antigen-specific CD4 1 T cells. Butyrate-treated RADCs (Bu-RA-DCs) decreased CD11c, but increased CD103 and a 4 b 7 expression. Moreover, the CD4 1 T priming capability and the levels of retinal dehydrogenase of RA-DCs were suppressed significantly by butyrate. Thus, butyrate and retinoic acid have different but synergistic regulatory functions on mucosal DC differentiation, indicating that immune homeostasis in the gut depends largely upon RA and butyrate to imprint different mucosal DC subsets, both individually and collectively.
Introduction
It is well known that intestinal mucosa is the primary breeding place for flora and various foreign antigens. Thus, it is necessary for the mucosal immune system to create a protective immune response or to maintain tolerance [1] . As with antigen-presenting cells, dendritic cells are virtually omnipresent and play a pivotal role in instructing the initiation and activation and controlling the effects of the antigen-induced immune response in peripheral immune organs, as well as immune tolerance in the gut [2] . Dendritic cells (DCs) are remarkably plastic and have a notable ability to adapt to the resident microenvironment through modification of their phenotypes and functions [3] . Since the discovery of DCs, various DC subsets, which show dramatically different phenotypes and immune functions, have been identified [4, 5] . In mucosal tissue there are at least two different DC subsets, depending on the expression of CD103, and these DCs decide gut tolerance and intestinal inflammation [6, 7] . Accumulating data have shown that metabolites or products derived from commensal bacteria have contributed greatly to the development, homeostasis and properties of DCs in the mammalian gastrointestinal tract [8, 9] . If the composition or metabolism of the microflora is altered, inflammatory diseases such as inflammatory bowel disease (IBD), atherosclerosis and even colon cancer might be induced [10] . Thus, these distinctive DC subsets and maintenance of a tolerant gut immune microenvironment depend largely upon the interaction between DCs and commensal bacterial populations.
In recent decades, studies have shown that vitamin Aderived retinoic acid (RA) plays vital roles in maintaining gut immune homeostasis through the induction of gut homing in lymphocytes and the differentiation of regulatory T cells (T reg ) [11] . It also has been shown that RA has the capability to promote the development of mucosal DCs, including intestinal CD103
1 CD11b -(cDC1) and CD103
1

CD11b
1 (cDC2) cells [9] . In addition to RA, the fates of intestinal immune cells in the gut are also decided by many other factors, especially signals from commensal bacteria and their metabolites, such as short chain fatty acids (SCFAs) [12] . As one of the richest SCFAs in the gut, butyrate is produced by intestinal bacteria through the fermentation of plant fibre, and functions in inducing the differentiation of T reg cells [13] . Furthermore, studies have shown that lower levels of butyrate were detected in the lumen of patients with colitis, indicating a potential function of butyrate in regulating immune function in the gut [14] . Unfortunately, at present, the exact role of butyrate in the differentiation of RA-induced mucosal DCs is still not well demonstrated. In this study, by co-culturing butyrate with RA to imprint bone marrow cell differentiation into DCs in vitro, we observed that butyrate co-operates with RA to induce mucosal-like DC differentiation. These results indicate a potential contribution of butyrate in maintaining gut immunity with tolerance properties. on a Bio-Rad iCycler. Primers were synthesized by the Sangon Biotech Company (Shanghai, China). Total amounts of DNA were calculated using the 2 -DDCt method, and the relative mRNA levels of target genes were normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The sequences of primers were as follows:
Materials and methods
Mice
GAPDH, forward 5 0 - GGCATTGCTCTCAATGACAA-3' , reverse 5 0 -TGTGAGGGA GATGCTCAGTG-3 0 ; IL-6, forward 5 0 -GAGGAGACTTCA CAGAGGATAC-3 0 , reverse 5 0 -GACTCTGGCTTTGTCTTT CTTG-3 0 ; IL-12, forward 5 0 -GGTTTGCCATCGTTTTG-3 0 , reverse 5 0 -GGGTCTTTCCAGAGCCT-3 0 ; TNF-a, forward 5 0 -GAACTGGCAGAAGAGGCACT-3 0 , reverse 5 0 -GGTCT GGGCCATAGAACTGA-3 0 ; Nos2, forward 5 0 -CCAAGCCCT CACCTACTTCC-3 0 , reverse 5 0 -CTCTGAGGGCTGACACAA GG-3 0 ; ALDH1A2, forward 5 0 -ACCGTGTTCTCCAA CGTCACTGAT-3 0 , reverse 5 0 -TGCATTGCGGAGGATACCA TGAGA-3 0 .
Griess reaction
The concentration of nitric oxide (NO) in samples was determined using the Griess reaction kit (Beyotime, Nanjing, China), according to the manufacturer's protocol. The NO concentrations in samples were determined quantitatively based on their correspondence to the absorbance from the standard plot. Aldehyde dehydrogenase (ALDH) activity assay ALDH activity in cells was determined by using the ALDE-FLUOR staining kit (StemCell Technologies), according to the manufacturer's instructions. ALDEFLUOR-stained cells were analysed using the FACSCalibur flow cytometer.
Antigen-specific CD4 1 T cell proliferation assay in vitro DC cells were prepared as described previously and incubated with 1 mg/ml OVA 323-339 peptide (Sigma-Aldrich) at 378C in a 5% CO 2 incubator for more than 6 h to prepare OVA 323-339 -loaded DCs. OVA 323-339 peptide-specific CD4 1 T cells were collected from the spleens of C57BL/ 6 3 DO11.10 F1 mice and purified using a CD4 ) were seeded into a round-bottomed 96-well plate in 200 ll medium, then cocultured further in 5% CO 2 at 378C for 4 days. On day 5, cells were harvested and incubated with fluoresceinconjugated CD4 and CD25 antibodies and analysed by flow cytometry.
ELISA analysis for cytokines
The concentrations of IL-2 or IL-12p70 in the supernatant were determined, respectively, using an enzyme-linked immunosorbent assay (ELISA) kit (eBioscience), according to the manufacturer's protocol.
Statistical analysis
The experimental data are presented as the mean 6 standard error of the mean (s.e.m.). The statistical analysis was performed using one-way analysis of variance (ANOVA) in Graphpad Prism version 5; P < 0.05 was considered to be statistically significant.
Results
Butyrate modifies the phenotype of RA-DCs BM cells were cultured with GM-CSF/IL-4 with or without Bu and RA. As shown in Fig. 1a-c , there was no significant difference in the total cell numbers, cell size or cell divisions in different DCs. CD11c is one important biomarker of dendritic cells [15] . Comparing BMDCs and RA-DC cells, the expression of CD11c on Bu-DC (GM-CSF/IL-4/Bu) and RA-Bu-DC (GM-CSF/IL-4/RA/Bu) was inhibited dramatically (Fig. 1d) . Both co-stimulatory molecules and MHC-II molecules play important roles in DC-mediated antigen presentation and T cell activation. The data in Fig.  2a show that the levels of CD80, CD86, MHC-II and B7-DC on DCs were obviously inhibited in RA-DCs. CD103 is a biomarker of a proportion of mucosal DCs (CD103 1 DC)
in mesenteric lymph nodes (MLNs) and colonic lamina propria (LP). The results in Fig. 2a show that RA treatment increased the level of CD103 in DCs (RA-DC) significantly while butyrate had no effects, similar to DC treatment with RA. If DCs were treated with retinoic acid and butyrate simultaneously, higher CD103 were detected on DCs (RABu-DC) (Fig. 2a) . Interestingly, butyrate was found to have synergistic effects with RA in terms of the expression of gut homing receptor a 4 b 7 in DCs (Fig. 2b) .
Lower proinflammatory cytokines secreted by butyrate and RA-induced DCs
Next, we investigated the effects of butyrate and retinoic acid on the cytokine profile of DCs. The data in Fig.  3a ,b,d,e show that both butyrate and retinoic acid treatment suppressed the expression of IL-6, tumour necrosis factor (TNF)-a and IL-12 in DCs (RA-DC, Bu-DC and RA-Bu-DC), which was detected using qPCR and ELISA. Interestingly, lipopolysaccharide (LPS)-treated BMDCs upregulated nitric oxide synthase 2 (NOS2) levels and produced more NO, but these compounds were inhibited significantly in all RA and/or butyrate treated DCs (Fig. 3c,f) . Thus, lower levels of proinflammatory cytokine secretion were detected in RA-and/or butyrate-treated DCs.
Butyrate regulates the priming functions of RA-DCs on CD4 1 T cells
A hallmark of DCs is their ability to stimulate antigenrestricted T cell activation and proliferation. Comparing the priming capabilities of different DCs in Fig. 4a , we found that RA-treated DCs (RA-DCs) showed a decreased ability to prime CD4 1 T cell proliferation than DCs/LPS. Remarkably, the proliferations of CD4 1 T cells were suppressed more significantly in both Bu-DCs and RA-Bu-DCs compared to RA-DCs (Fig. 4a) . This was confirmed further by detecting the levels of IL-2 in the supernatant of DC/CD4 1 T cells culture wells (Fig. 4b) . We next assessed the function Y. Qiang et al.
of RA and/or butyrate on regulatory T cell differentiation in vitro. The data in Fig. 4c show that RA treatment obviously promoted CD4 1 T reg cell differentiation. Unfortunately, fewer FoxP3 1 T cells were found in butyrate-treated groups, indicating that butyrate itself displays inefficient regulation of the differentiation of CD4 1 regulatory T cells. Furthermore, the data in Fig. 4d show lower levels of IL-2 in RADCs and RA-Bu-DCs, indicating that T reg cells consumed more IL-2 proteins in these groups.
Butyrate inhibits the activity of retinal dehydrogenase in RA-DCs
The metabolism of retinoic acid depends largely upon the function of members of the retinal dehydrogenase family, especially ALDH1a2. The data in Fig. 4e show that ALDH1a2 could be detected in the BMDCs and increased further in response to LPS stimulation. Similar to previously reported data, RA treatment increased the ALDH1a2 activity in RA-DCs. It is worth noting that the activities of ALDH1a2 were suppressed dramatically in both groups of butyrate treated DCs (Bu-DC and RA-Bu-DC).
Discussion
The exact effect of butyrate on the differentiation of RAinduced mucosal DCs has not been elucidated thoroughly to date. In this study, we observed that butyrate treatment suppressed the expression of co-stimulatory MHC-II molecules but increased the levels of CD103 and a 4 b 7 in RAinduced DCs (RA-Bu-DCs). Moreover, the decreased capability of RA-DCs to prime OVA 323-339 peptide antigenspecific CD41 T cell proliferation was inhibited by butyrate. Thus, this study shows that butyrate had synergistic functions with RA to induce mucosal-like DC differentiation from bone marrow cells in vitro. DCs work as the conductor in deciding the results of an immune response. As one of the DC subsets, CD103
1 DCs represent the DC population in the intestinal LP and the MLN, and play an important role in mediating immunological tolerance in the gut [16, 17] . This is largely dependent upon the relationship between the flexibility of CD103 1 DCs and gut microenvironment. Evidence shows that retinoic acid induces DC cells to express a 4 b 7 , and confers mucosal DC properties on them [9, 18, 19] . These data indicate the direct effects of retinoic acid on the differentiation of gutresident DC cells. Here, we found that RA treatment promoted BMDC differentiation with mucosal-like DC properties. RA-treated cells express higher CD103 and a 4 b 7 expression, but decreased the ability to induce antigen CD4 1 T cell proliferation (Fig. 4) . Indeed, the positive expression of CD103 and a 4 b 7 indicate that these RA-DCs were endowed with the correct set of homing receptors for subsequent entry into mucosal effector tissues. Moreover, these RA-DCs have a reduction in the production of proinflammatory cytokines (TNF-a, IL-6) and IL-12 ( Fig. 3 ) and exhibit promotion of T reg cell differentiation (Fig. 4) . Studies have shown that bacterial members of the clostridium, bacillus and butyrivibrio genera can produce and maintain high concentrations of butyrate in the small intestine and colon. Published works show that butyrate regulates the differentiation and maturation of DCs, and changes the cells' capability to capture and prime antigen-specific T cell activation [20, 21] . These characteristics were confirmed in both butyrate-treated DC groups (Bu-DCs and RA-Bu-DCs) in this study, indicating the potential roles of butyrate in the gut. Outside the intestine, dietary fermentable fibre can also shape the immunological environment in the lung and influence the severity of allergic inflammation through SCFAs [22] . Interestingly, we found that CD103 and a 4 b 7 expression were only increased in RA-treated DCs (RA-DCs and RABu-DCs), suggesting that CD103 induced transcription is related closely to vitamin (retinol) metabolism, not to butyrate.
Certain mucosal DC subsets have reduced ability to prime CD4 1 T proliferation than DC cohorts in peripheral tissue. Indeed, the priming ability of CD4 1 T cell activation and proliferation was impaired seriously in all RA-DCs, Bu-DCs and RA-Bu-DCs (Fig. 4) , indicating the regulatory functions of RA and butyrate on DCs. Studies have also shown that CD103 1 DCs can induce the generation of FoxP3 1 regulatory cells from naive T cells in the presence of retinoic acid [16] . Other studies also revealed that RA stifles autoimmunity through up-regulating T reg cell development, thus inhibiting the ongoing autoimmune disease [23] . We noticed that retinoic acid-treated DCs (RA-DCs and RA-Bu-DCs) had a stronger capability to induce T reg cell differentiation, which was not inhibited significantly with butyrate treatment (Fig. 4) . A series of contradictory statements exists in published data regarding the effects of butyrate on T reg cells [24, 25] . The exact role of SCFAs on T cell differentiation still needs more exploration.
In mammals, vitamin A is taken from food in the form of retinol, retinoic ester or beta-carotene. In the cell, retinol can be oxidized into retinal by retinol dehydrogenase (RDH) and then turn into retinoic acid by retinaldehyde dehydrogenase (ALDH) [26] . Accumulating data have shown that intestinal CD103
1 DCs express retinal dehydrogenase (ALDH) 2 highly, which works as an enzyme to convert retinal to RA and then induce gut-homing T and B cells [27] . Furthermore, DCs can acquire high levels of retinoic acid-producing capacities in response to vitamin D 3 [28] . Here, our data also confirmed that the levels of RALDH were increased in RA-treated DCs (RA-DCs) (Fig.  4) , indicating the importance of RA in the differentiation of immune cells in the gut. Unfortunately, the exact role of butyrate on ALDH is waiting to be demonstrated. Data from high-fibre feeding models showed that fibre-derived SCFAs, particularly acetate and butyrate, enhanced oral tolerance and protected against food allergy by enhancing ALDH activity in CD103 1 DCs in vivo [28] . In contrast, our data showed that butyrate inhibited the levels of ALDH in DCs c, f) . The mRNA levels of nitric oxide synthase 2 (NOS2) in DCs (c) and NO in the supernatants (f) were quantified with qPCR and the Griess reaction, respectively. Data are shown as the mean 6 standard error of the mean. *P < 0Á05; **P < 0Á01; ***P < 0Á001.
Butyrate and RA imprint mucosal-like DCs significantly. The research model used in the experiments may have caused this difference. Previous studies also showed that butyrate significantly induced IL-23 expression and promoted IL-17 secretion, indicating its contribution to increasing the severity of dextran sulphate sodium (DSS) colitis [29] . Interestingly, one colonic DC subset (CD103 1 CD11b 1 ALDH -) was identified recently, which displays a unique capacity to polarize T helper type 17 (Th17) cells [30] . Similar to the CD103 Collectively, the data in this study suggest that CD103 1 mucosal DC subsets, which control T cell homeostasis in the gut, are dependent upon the regulation of butyrate and RA, both individually and collectively.
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